Filing Flows › PTC Therapeutics (PTCT) › How it makes money
How PTC Therapeutics (PTCT) makes money
PTC Therapeutics (PTCT) made $358M of revenue in the third quarter 2026 (Q3 2026), +70% from a year earlier. Net product revenue brought in $276M (77%); Royalty revenue brought in $81.7M (23%); Collaboration and license revenue brought in $229K (0%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Net product revenue | $276M | 77.1% | +16% | +111% |
| ↳ Sephience | $182M | 50.8% | +20% | +830% |
| ↳ Translarna | $48.5M | 13.6% | +15% | -4% |
| ↳ Emflaza | $25.1M | 7.0% | +2% | -29% |
| ↳ Upstaza/Kebilidi | $14.6M | 4.1% | +30% | -8% |
| ↳ All other products | $5.9M | 1.6% | -38% | -40% |
| Royalty revenue | $81.7M | 22.8% | +15% | +15% |
| Collaboration and license revenue | $229K | 0.1% | -100% | -98% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $358M | 100.0% |
| Income tax | $10.6M | 3.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $358M | +70% |
| Q2 2026 | $361M | +102% |
| Q1 2026 | $273M | -77% |
| Q4 2025 | $165M | -23% |
| Q3 2025 | $211M | +7% |
| Q2 2025 | $179M | -4% |
| Q1 2025 | $1.2B | +460% |
From PTC Therapeutics' 10-Q filed Oct 29, 2026 (on EDGAR).
Questions
How does PTC Therapeutics make money?
PTC Therapeutics (PTCT) made $358M of revenue in the third quarter 2026 (Q3 2026), +70% from a year earlier. Net product revenue brought in $276M (77%); Royalty revenue brought in $81.7M (23%); Collaboration and license revenue brought in $229K (0%).
What is PTC Therapeutics' biggest business?
Net product revenue: $276M in the third quarter 2026, 77% of revenue, +111% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.